Our data also demonstrate that TTFields treatment without RT results in more than 50% and 88% reduction of surviving fraction in U-118 MG (MGMT methylated) and LN-18 cells (MGMT un-methylated) respectively, providing further evidence of TTFields’ efficacy against glioma cells regardless of the MGMT methylation status. Here, MGMT is linked to central nervous system cancer.